Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B7-H3-CAR T Cells in Newly Diagnosed High-Risk Osteosarcoma
NCT07428993Phase 2Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Aug 2026
- Primary completion
- Dec 2034
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in osteosarcoma (OS), sponsored by St. Jude Children's Research Hospital. Primary endpoint: Event-Free Survival at 24 months. Started Aug 2026; status: recruiting.
02
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT07428993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07428993.